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Prostanoids can be classified into prostacyclins, prostaglandins and 
thromboxanes, and they are synthesized from arachidonic acid through the action of 
various enzymes such as cyclooxygenase. Prostanoid receptors are widely distributed 
in our body; activation of these receptors will lead to different physiological events, 
such as vasoconstriction. 
Thromboxane A2 (TP) receptor is a member of thromboxane receptors and 
belongs to the G-protein-coupled receptor superfamily. The gene encoding TP 
receptors is situated on chromosome 10 and chromosome 19 in mouse and human 
respectively. Previous studies show that blockade of TP receptors inhibits the 
development of cardiovascular diseases such as atherosclerosis. On the other hand, 
some other studies demonstrate that activation of TP receptors modifies vascular 
reactivity but the underlying mechanisms have not been explored. The first part of this 
study focuses on the impact of TP receptor activation on nitric oxide-mediated 
vasorelaxation. And the second part deals with the effect of periadventitial fat on 
relaxation of blood vessels contracted by activation of TP receptors. 
Aortas of female Wistar rats (240 - 250 g) were dissected out and cut into ring 
segments. The aortic rings with and without endothelium were suspended in organ 
baths filled with Krebs solution and connected to a force transducer. Changes in 
isometric tension were recorded and measured. Contractile responses were expressed 
as active tension (absolute tension divided by dry weight of the ring). 
U46619 (10，30，and 100 nM), a TP receptor agonist, attenuated the 
vasorelaxation of rings without endothelium in response to sodium nitroprusside (3 
nM - 10 nM), hydroxylamine (3 nM - 100 ^iM), and SIN-1 (3 nM - 30 in a 
concentration-dependent manner. Likewise, the presence of U46619 also impaired 
iv 
endothelial nitric oxide-dependent relaxation to acetylcholine (3 nM - 10 )iM) in 
rings with endothelium. The U46619-induced inhibition of vasorelaxation was 
abolished by the TP receptor blocker, SI8886 (0.3 ^iM), Rho kinase inhibitor, Y27632 
(4 )J,M without endothelium and 2 JLIM with endothelium), and phosphodiesterase 
inhibitor, IBMX (20 |iM without endothelium and 5 |iM with endothelium). 
The present results show that (i) activation of the TP receptor inhibits 
vasorelaxation to nitric oxide/cyclic GMP dependent dilators, and (ii) this inhibition 
was likely to be mediated through the stimulation of Rho kinase and 
phosphodiesterases. 
Most of the blood vessels are surrounded by periadventitial fat. However, there 
are only limited studies on the modulatory role of periadventitial fat in the generation 
of arterial tone. No studies have ever examined the role of periadventitial adipose 
tissue in vasorelaxation. In this set of experiments, the influence of periadventitial fat 
on relaxation of female Wistar rat aortas in response to various vasorelaxants was 
investigated. 
In phenylephrine (3 p.M)-contracted rings, the vasorelaxation can be readily 
triggered by acetylcholine (3 nM - 10 |iM) and sodium nitroprusside (3 nM - 10 |iM) 
in the absence or presence of surrounding fat. On the contrary, when U46619 (100 nM) 
was used, the relaxation to both acetylcholine and sodium nitroprusside were 
enhanced in rings with periadventitial fat as compared with that in rings without 
periadventitial fat. This enhanced relaxation was attenuated in rings bathed in a 20 
mM K+-containing solution and abolished in the presence of 60 mM K+. These results 
suggest that periadventitial fat exerts an anti-contractile effect which appears to be 
specific to contraction induced by the TP receptor activation and this effect is 
probably related to opening of K+ channels. 
V 
Summary 
The present study has proposed a possible mechanism that may mediate the 
inhibitory effect of TP receptor activation on NO/cyclic GMP-dependent 
vaso-relaxation. Y27632 and IBMX reduce such inhibitory effect, indicating that 
stimulation of Rho kinase and phosphodiesterase is likely to be involved. In addition, 
the anti-contractile action of periadventitial fat was observed in U46619-induced 
vasocontraction, which was reduced or even abolished with increasing extracellular 
K+ concentrations, suggesting that unknown periadventitial adipose tissue-derived 
relaxing factors in U46619-contracted aortic rings may open K+ channels as part of 
the mechanism that contributes to the increased vasorelaxation. 
The aforementioned results need confirmation in human blood vessels. Further 
experiments will be designed to determine the pathological role of Rho kinase and 
phosphodiesterase in vascular diseases, such as hypertension and diabetes, and also to 
investigate the vascular benefits of Rho kinase inhibitors, phosphodiesterase inhibitors, 
and TP receptor antagonists. The novel findings about the impact of periadventitial fat 
on the regulation of vasorelaxing mechanisms may open a new area in vascular 
research, which shall hopefully provide us with new pharmaceutical targets against 




( P r o s t a g l a n d i n )和血栓素（T h r o m b o x a n e )三種’它們都是以花生油酸 
(Arachidonic a c i d )爲原料而合成，當中涉及多種不同的酶，如環氧合酶 
(Cyclooxygenase)�前列線素類受體廣爲分佈在身體上。當前列線素類受體被 
激活時’身體會出現多種如血管收縮等的生理反應。 
血栓素A 2 (Thromboxane A2，TP)受體是血栓素受體的一員’屬於G-蛋白 












血管對 sodium nitroprusside (3 NM - 10 jiM) ’ hydroxylamine (3 NM — 100|J.M)禾口 
SIN-1 ( 3 n M - 3 0 |iM)的舒張反應，U46619的濃度越高，削弱的幅度越大。同 
樣地，U46619也減少了內皮完整的血管對Acetylcholine (3 n M - 1 0 nM)所引 
發的依靠內皮一氧化氮之舒張反應。這種由U46619所做成的抗舒張作用能被 
TP受體阻段藥S18886 (0.3 i^M), Rho激酶抑制劑Y 2 7632 (被移除內皮的血管， 
4 ^M;完整內皮的血管，2 i iM)和磷酸二酯酶抑制劑 IBMX (被移除內皮的血 
管，20 nM;完整內皮的血管，5 ^M)所移除0 







在被phenylephrine (3 |uM)所收縮了的血管段環中，無論有無脂肪組織包圍， 
Acetylcholine (3 nM - 10 [iU)和 Sodium Nitroprusside (3 nM - 10 ^iM)都能將 
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1.1. Thromboxane A2 (TP) Receptors 
1.1.1. Gene structure of human TP receptors 
The human thromboxane A2 receptor gene was cloned in 1991 (Hirata et ai, 
1991). The gene exists as a single copy and contains 15 kilobases (kb). 3 major exons 
and 2 introns are found within the gene, the 5’ untranslated region region (UTR) 
sequence is located in exon 1 while exon 2 and exon 3 are the main coding exons 
(Coyle et al., 2002). The TP receptor gene contains 3 distinct promoters namely PI, 
P2 and P3. PI and P3 are located in 5' of exon 1 and exon 2 respectively, while P2 is 
situated in a noncoding exon within intron 1 (Niising et al., 1993; Coyle et al, 2002). 
The gene can be found in 19pl3.3 of human chromosome. 
1.1.2. Isoforms of TP receptor 
It was a controversial issue that whether subtypes of TP receptor existed when 
the gene of the receptor was first cloned. Differences in pharmacological properties 
and ligand binding profiles of the TP receptors in various tissues implied the existence 
of TP receptor subtypes (Mais et al., 1985; Morinelli et al., 1989). On the other hand, 
opposite results were also obtained by other groups of researcher (Swayne et al” 1988; 
Hanasaki et al, 1988，1989). Until 1994，a group of investigators found out a novel 
differential splicing mechanism of the TP receptor gene could result in subtypes of 
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that receptor (Raychowdhury et al., 1994), the truth was finally revealed. 
There are two isoforms of TP receptor in humans, called TP receptor a (TPa) 
and TP receptor (3 (TPp). TPa and TPp contain 343 and 407 amino acid residues 
respectively. The 328 amino acid residues in the N-terminal of TPa and TPp are the 
same, but their carboxyl terminal sequence are different (Hirata et al” 1991; 
Raychowdhury et ai, 1994). 
1.1.3. Distribution and expression of TP receptors in human 
Most of the human cells and tissues express both TPq and TPp. In most cell 
types, more TPa mRNA is found, and the liver hepatoblastoma Hep G2 cell line even 
only express TPa mRNA (Miggin et aL, 1998; Habib et al.’ 1999). The amount of TPa 
mRNA is the same in most examined cells and tissues, however, the variation of TPp 
mRNA expression is huge. In the vascular smooth mucle (VSM), the situation is 
similar. Both TPq and TPp are equally expressed In human foetal aortic VSM cells, but 
in human adult aortic VSM cells, TPa is predominately expressed (Miggin et al” 
1998). The relative TP receptor isoform expression data in various tissues and cells 
are summarized in table 1.1.3A. The differential expression of TPa and TPp is 
complex and more investigations are required to further explain the physiological role 
of such differential expression. 
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Table 1.1.3A. TP receptor isoform expression ratio in various tissues 
Tissue/Cell line TPa / TPp 
Foetal VSM 1.16±0.16 
Adult VSM 2.37 ± 0.43 
Uterine smooth muscle cell 3.24 土 0.09 
Primary human umbilical vein 5.81 士 0.53 
endothelial cells (1° HUVECs) 
Foetal brain 2.12 ±0.25 
Adult brain 1.97 ±0.33 
Thymus 3.31 ±0.15 
Small intestine 1.51 ±0.12 
Liver 2.71 士 0.17 
HepG2 ^ 
Data adopted from Miggin et al., 1998 
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1.1.4. Signal transduction of TP receptors 
The signal transduction mechanism of receptor activation is always crucial to 
pharmacologists, TP receptors have no exception. TP receptors belong to the 
G-protein coupled receptor (GPCR) superfamily, G-proteins play an important role in 
the signal transduction cascade of the receptors (Brass et al., 1987; Hirata et al., 1991; 
Shenker et al., 1991). The development of specific pharmacological blockers and 
genetic lock out/lock down animals gave reseachers many important clues about the 
mechanism behind the receptor activation process. However, even with the help of 
those specific blockers and genetic modified animals, the signaling mechanisms 
related to TP receptor activation remain controversial. The controversies are probably 
related to the complexity of the signal transduction mechanisms of TP receptors 
(Cogolludo et al., 2003). 
Most of TP receptors are linked to phospholipase C (PLC) via Gq. When an 
agonist binds to the receptor, PLC will be activated forming 1,4,5-triphosphate (IP3) 
and diacylglycerol (DAG) (Himpens et al” 1990; Shenker et al” 1991; Gerald et al., 
1993). IP3 will cause increases in cytoplasmic calcium where DAG will activate 
protein kinase C (PKC). Although both TPa and TPp can activate phospholipase C 
(PLC), they are found act differently to adenylyl cyclase. Stimulation of TPa in human 
blood platelets can activate adenylyl cyclase but activation of TPp inhibits it (Takahara 
et al., 1990; Hirata et al., 1996). This phenomenon implies that isoforms of TP 
receptors may co-operate to control complex physiological events such as platelets 
aggregation. 
In VSM cells, the activation of TP receptors can trigger Ca^ "^  sensitization, 
which characterized by generating a huge contractile response with little increase in 
internal Ca^^ level when the receptor is activated by agonists (Himpens et al., 1990; 
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Wilson et al., 2005). Right after the TP receptors are activated, the G12/13 family of 
heterotrimeric G proteins will be recruited. The heterotrimeric G proteins will then 
stimulate a guanine nucleotide exchange factor (GEF), resulting in activation of 
GTPase RhoA (Somlyo et al., 2000; Hartshome et al., 2004). The activated GTPase 
Rho A will cause Rho-associated kinase (ROK) to phosphorylate the myosin targeting 
subunit of the myosin light chain phosphatase (MLCP) MYPTl at Thr-855 (Velasco 
et al., 2002; Sward et al., 2003), which will inhibit the MLCP. On the other hand, 
evidences show that activated ROK will also mediate Ca^ "^  entry through L-type Ca^^ 
channels or non-selective cation channels, which will result in Ca^+Zcalmodulin 
dependent myosin light chain kinase (MLCK) activation and cause vasoconstriction 
(Maeda et aL, 2003; Ghisdal et al” 2003; Shabir et al, 2004). The proposed signal 
transduction mechanism of TP receptor activation in VSM cells is summarized in 
Figure 1.1.4 A. 
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Fig. 1.1.4A. Graphical presentation of the proposed signal transduction 
cascade meadiated by activation of TP receptor in VSM cells. Black 
arrow indicates "activation" or "lead to”，grey and purple arrows mean 
“separate into". 
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1.1.5. Major agonists of TP receptor in animals and humans 
1.1.5.1. Thromboxane A! 
Thromboxane A2, one of the major thromboxanes, is produced mainly by 
activated platelet (Hirsh et al.’ 1981; Fitzgerald et al., 1988; Narumiya et al., 1999). 
Synthesis of thromboxane A2 involves conversion of arachidonic acid through the 
action of enzymes cyclooxygenases (COX) followed by thromboxane synthetase 
(Vane JR, 1971; Ramwell et al； 1977; Narumiya et al, 1999). 
When the platelets encounter specific agonists such as ADP, thrombin and 
collagen, arachidonic acid will be released from the platelets cell membrane by the 
action of phospholipases (Malmesten et al, 1975; Flower and Blackwell, 1976; 
Claesson and Malmesten, 1977; Paul et al., 1999). Using the liberated arachidonic 
acid as materials, the platelets will produce and then release thromboxane A2. The 
released thromboxane A2 stimulates and recruits more platelets to accelerate the 
platelet aggregation process, an example of positive feedback mechanism (Hourani 
and Cusack, 1991). 
The half life of thromboxane A2 is relatively short (ti/2 at 37°C = 30s) 
(Hamberq et al., 1975), resulting in difficult detection of it. Due to that reason, 
researchers normally measure thromboxane B2. the stable inactive hydration product 
of thromboxane A2, in blood plasma or urine to indirectly monitor the thromboxane 
A2 level in the body (Fitzgerald et al, 1983; Lellouche et al., 1990). 
1.1.5.2. Prostaglandin H2 
Apart from thromboxane A2, TP receptors can also be activated by 
prostaglandin H2. 
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Similar to thromboxane A2, Prostaglandin H2 is synthesized from 
arachidonic acid through the action of COX (Vane JR, 1971; Ramwell et al., 1977). 
Prostaglandin H2 is the precursors of many eicosanoids including thromboxane A2. By 
undergoing chemical changes catalised by different enzymes, various eiconsanoids 
can be formed. For example, prostaglandin D2 (PGD2) is formed from the action of 
prostaglandin D2 synthase on prostaglandin H2 (Moncada and Vane, 1978; Lewis et 
al., 1982; Narumiya et al,, 1999). 
Although both prostaglandin H2 and thromboxane A2 bind to TP receptor 
triggering similar physiological events (Furci et al., 1991)，their affinity to TP 
receptors are not the same. Prostaglandin H2 was found 3 times less potent than 
thromboxane A2 on TP receptors (Mayeux et al., 1988). 
Interestingly, prostaglandin H2 (ti/2 at 3 7 � C = 5 min) (Halushka et al., 1989) 
are more stable than thromboxane A2. The longer half-life may partly compensate for 
its relatively lower affinity to the TP receptor, and thus explains the potency of 
prostaglandin H2. 
1.1.6. Functional studies: effect of TP receptor activation and blockade on 
vascular tone and atherosclerosis 
1.1.6.1. Effect of TP receptor activation 
1.1.6.1.1. On vaso-contraction 
9,11-dideoxy-ll oc , 9 oc -epoxymethanoprostaglandin F2a (U46619) is 
commonly used as a TP receptor agonist in cardiovascular research (Coleman et al., 
1 
1981). Activation of the TP receptor by U46619 causes rapid vaso-contraction in both 
arteries and veins. Similar to phenylephrine, the degree of contraction mediated via 
TP receptor activation changes with different treatments. Nobe showed that high 
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glucose enhanced the U46619-induced spontaneous phasic contraction in mouse 
portal vein (Nobe et al, 2003，2004)，and this contraction enhancement can be 
suppressed by diacylglycerol kinase inhibitor, suggesting that the TP receptor may 
play a more active role in modulation of arterial tone in a hyperglycemic condition. 
1.1.6.1.2. On vaso-relaxation 
In 2002, Streefkerk et al described that U46619 can 
concentration-dependently reduce the vaso-relaxation initiated by various 
vaso-dilators in rat aortas (Streefkerk et al., 2002), but very little explanation 
concerning the phenomenon is given in the report. 
1.1.6.2. Effect of TP receptor blockade 
1.1.6.2.1. On endothelium dependent vaso-contraction 
Blockade of TP receptor by specific antagonists such as AH 23848 and SQ 
29548 abolishes the endothelium dependent vaso-contraction initiated by 
acetylcholine (Auch-Schwelk et al., 1990). In the same report, the authors mentioned 
that thromboxane synthetase inhibitors shows no effect on endothelium-dependent 
vaso-contraction triggered by acetylcholine (Randall et al, 1981; Liischer et al., 
1986)，In addition, the amount of other prostaglandin Kb metabolites under stimulation 
of acetylcholine either shows no significant differences or below detectable level, 
implying that the TP receptor activation may be caused by agonists apart from the 
major one such as thromboxane A2 and prostablandin H2. 
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1.1.6.2.2. On animal models related to atherosclerosis 
Apart from the endothelium-dependent vaso-contraction, blockade of TP 
receptors affects the development of atherosclerosis in animals. It was reported that 
the selective TP receptor blocker, SI8886 slowed down the development of 
atherosclerosis in rabbit iliac arteries by inhibiting the local inflammatory process 
(Worth et al” 2005). In another similar study using rabbit as animal model, magnetic 
resonance imaging showed that blockade of TP receptors by SI 8886 not only reduced 
the rate of atherosclerotic pathogenesis, but also stabilized the lesion within the 
affected vascular wall (Viles-Gonzalez et aL, 2005). In the same year, another 
research group provided evidence that by blocking the TP receptor activities, the 
diabetes-associated inflammation and atherosclerosis in streptozotocin-treated mice 
was inhibited (Zuccollo et.al., 2005). In 2006, Xu et al, also found that treatment with 
SI8886 on diabetic mice reduced the urine oxidative stress markers and suppressed 
diabetic neuropathy (Xu et al., 2006). 
1.1.7. Objectives of current study 
U46619 can concentration-dependently reduce the vaso-relaxation initiated by 
various vaso-relaxants in rat aortas (Streefkerk et al., 2002)，there are either caused by 
the agonistic nature of U46619 or its non-specific effect. As U46619 is proven to be a 
specific thromboxane A2 receptor agonist (Hourani and Cusack, 1991)，it is 
reasonable to hypothesize that such inhibitory effect is mediated through thromboxane 
A2 receptor. 
Since thromboxane A2 is unstable and prostaglandin H2 does not show high 
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specificity to the TP receptor (Hamberq et al., 1975; Mayeux et al., 1988; Halushka et 
al., 1989), we have to use the synthetic TP receptor agonist. Among the synthetic 
thromboxane A2 agonist available, U46619 is widely used and the specificity is high 
(Auch-Schwelk et al., 1990; Hourani and Cusack, 1991). As a result, U46619 is used 
to test the hypothesis that activation of the TP receptor will cause an inhibitory effect 
on cyclic GMP-dependent vaso-relaxation. In addition, this study also aims to 
investigate the mechanisms that mediate such phenomenon. 
a 
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1.2. Periadventitial Adipose (Fat) Tissue 
1.2.1. General function, distribution and classification of fat 
Fat belongs to the category of connective tissue proper, and it is commonly 
regarded as a mixture of cells and tissues such as adipocytes, fibroblast, nerves and 
collagen fibres. Fat can be found in many places in human bodies, the relative 
distinctive sites involving subcutaneous region, breast, buttocks, bony sockets behind 
the eyes, pericardial area, space behind the kidneys and surroundings of arteries and 
veins. 
Except for storing lipid, adipose tissue also acts as insulator to heat loss, 
provides padding and cushions shocks. However, recent studies suggest that apart 
from these traditional functions, adipose tissues, especially adipocytes actually plays 
an important endocrine and paracrine role in regulation of normal physiological 
events, this area will be introduced at later part of this chapter. 
Adipose tissues can be generally classified into white adipose tissue and brown 
adipose tissue. White adipose tissue composes of the majority of the fatty tissue in the 
human body, which appears as a pack of pale yellow-white tissue. On the other hand, 
the brown adipose tissue has a deep brown appearance; it is because brown fat is 
highly vascularized, and the adipocytes within the brown adipose tissue contain a lot 
of mitochondria. These characteristics make brown adipose tissue a good heat 
generator. When they are stimulated by hormones or the nervous system, raid lipid 
metabolism will result and a significant amount of heat will be radiated out. The heat 
generated will be carried throughout the body by the surroundings highly vascularized 
circulation network. This is a very important mechanism in modulating body 
temperature in infants, since in infants, the normal heat homeostasis mechanisms, 
such as muscle shivering, has not been fully developed. Therefore heat releases from 
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brown adipose tissue contributes greatly to the temperature homeostasis in infants. 
1.2.2. Representative Endocrine/Paracrine Role of Adipose Tissues 
As mentioned, the traditional role of adipose tissues is confined to lipid storage, 
insulator and shock cushion. These viewpoints are critically challenged when a crucial 
factor, leptin, was discovered to be secreted by white fat adipocytes in 1994 by Zhang, 
et al. (Zhang et al., 1994). Thereafter, an increasing number of important factors that 
are produced and released from the adipocytes have been identified, e.g. adiponectin 
(Maeda et al., 1997)，angiotensinogen (Safonova et al., 1997)，tumor necrosis factor a 
(TNP-a) (Mohamed-Ail et al； 1998)，and resistin (Steppan et al, 2001). 
Since my studies also involve factors released from the adipose tissue in which 
their chemical nature is unknown. Introduction of some important and well defined 
protein and non-protein secretions from adipose tissues may give us a more complete 
general picture of this new research area. Besides, it may also give us insight to 
identify the nature of these unknown factors. In this section, two major vasoactive 
secretions from the adipose tissues will be briefly introduced. 
1.2.2.1. Leptin 
Leptin was discovered by Zhang and colleagues in 1994 (Zhang et al” 
1994) through studying the mutant ob/ob mice. Since leptin is found to be highly 
related to obesity, so it is also called obese protein (OB protein). Leptin is a 16 kDa 
protein, the gene product of the leptin (Lep(ob)) gene that encodes a protein with 18 
kD containing a signal sequence. The signal sequence will then be cleaved to produce 
a functional leptin with a size of 16 kDa (Zhang et al., 1994). 
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Many tissues and organs synthesize leptin, however, white adipose 
tissue remains to be the major site of its production (Trayhum et al, 1995, 1999, 
2001)，and body fatness of human subjects and experimental animals positively 
correlate with the circulating levels of leptin (Considine et al., 1996; Ostlund et al, 
1996). 
Leptin exerts its function through activation of the leptin receptor (Ob-R) 
(Lee et al., 1996). There are several types of Ob-R isoforms, among which, Ob-Rb 
contains the observable signal transduction domains and demonstrable signal 
transduction abilities, so it is believed that the actions of leptin are mainly mediated 
by Ob-Rb (Lee et al, 1996; Tartaglia, 1997). 
Physiological functions of leptin are very diverse. At early days, it was 
suggested that leptin mainly inhibits appetite (Ahima et al,, 1996). Later, additional 
functions are identified, from control of energy expenditure (Stehling et al., 1996)， 
regulation of T-cell mediated immune response (Lord et al., 1998)，manipulation of 
angiogenesis (Sierra-Honigmann et al, 1998) to inhibition of insulin secretion 
(Emilsson et al., 1997). 
Recent studies have suggested that the increased plasma leptin level is 
associated with higher cardiovascular risk; it maybe due to the ability of leptin to 
up-regulate C-reactive protein (CRP) which has pro-atherogenic effects on vascular 
endothelial cells (Pasceri et al., 2000; Khreiss et al., 2004). In addition, leptin can 
initiate both endothelium-dependent and -independent vaso-relaxation in isolated 
aortas and mesenteric arteries (Lembo et al., 2000; Matsuda et al., 2003). 
1.2.2.3. Angiotensinogen 
Except liver, the white adipose tissue is the biggest production site of 
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angiotensiongen (Safonova et al, 1997). The aforementioned major vasoactive 
signaling molecules secreted by the adipose tissue can induce vaso-relaxation. On the 
other hand, angiotensin II，which is converted from angiotensiongen through the 
action of renin and angiotensin converting enzyme, causes vasoconstriction by 
stimulating the angiotensin II receptor 1 (ATI) (Zhang et al” 2003). 
In obese subjects, the plasma level of angiotensinogen is increased and 
probably has a positive correlation with the mass of the white adipose tissue (Engeli et 
al., 2000). Increases in angiotensinogen also result in a raised local production of 
angiotensin II，since the white adipose tissue also express angiotensin-converting 
enzyme and ATI receptor (Harp and DiGirolamo, 1995; Engeli et al., 1999). Since 
angiotensin II is a potent vaso-constrictor, hypertension in obesity may be related to 
the increased secretion of its progenitor, angiotensinogen from the white adipose 
tissue (Engeli et al, 2000). 
1.2.3. Functional studies on vessels with periadventital fat attached — The 
beginning of the story of adipcyte-derived relaxing factor (ADRF). 
Periadventitial fat is the adipose tissue that surrounds most vessels. 
Traditionally, these surrounding tissues are regard as non-vasoactive and be routinely 
removed in functional study. In 1991, Soltis and Cassis demonstrated that 
periadvential adipose tissues could in vitro attenuate the vasoconstriction triggered by 
nor-adrenaline on Sprague-Dawley rat aorta (Soltis and Cassis, 1991). At that time, 
they thought such phenomenon was due to the uptake of noradrenaline by the 
periadventitial adipose tissues. In 2002, another group of researchers confirmed and 
further extended their idea with revealing more information behind the modulatory 
effect of periadventitial fat (Lohn et al., 2002). 
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Lohn et al. reported that apart from noradrenaline, periadventitial fat could also 
reduce the contractile force generated by the action of phenylephrine, 
5-hydroxytryptamine (5-HT) and angiotensin II. This effect did not depend on the 
functional endothelium. In addition, by donor-acceptor transfer bioassays, it was 
revealed that such anti-contractile effect was caused by a transferable factor in which 
the nature was unknown. Lohn et al. first used the term "adipocyte-derived relaxing 
factor (ADRF)" to describe the unknown factor. 
More studies indicate that the effect of periadventitial fat is likely due to the 
release of ADRFs. The anti-contractile ability of periadventitial adipose tissue is 
observable in human arteries in vitro. In 2004, the same research group found out the 
contraction of human mesenteric (Verlohren et al., 2004) could be partly attenuated by 
periadventitial adipose tissues. Similar results have also been reported on human 
internal thoracic arteries (Gao et al., 2005). These findings suggest that ADRF may 
also be involved in pathogenesis of human cardiovascular diseases. 
Apart from the large arteries, effect of ADRF is also observable in smaller 
arteries, suggesting that ADRF may play a role in controlling the total peripheral 
resistance which depends greatly on the small-sized arteries and arterioles. Verlohren 
et al. demonstrated that the periadventitial adipose tissue can inhibit the 
vaso-constriction by some common agonists such as phenylephrine and endothelin-1 
(Verlohren et al., 2004). In the same study, it is also pointed out that the 
anti-contractile effect increases with the amount of periadvential adipose tissue 
around the vessel rings (Verloliren et al., 2004). 
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1.2.3. Mechanisms behind the action of ADRF 
1.2.3.1. Nature of ADRF 
Until now, there is not too much information concerning the chemical 
structure of ADRF. Lohn et al. showed that the effect of the proposed ADRF can be 
abolished by heating (65 °C). In addition, ADRF could not be absorbed by serum 
albumin (Lohn et al., 2002). These results indicate that ADRF has a nature of proteins 
but not lipids. 
1.2.3.2. The mechanisms controlling the release of ADRF 
After Lohn et al. first introduced the concept of ADRF, the studies 
concerning its detailed mechanism of action have followed. In 2004, Dubrovska et al. 
proposed that the release of ADRF from periadventitial fat depended on the presence 
of extracellular calcium ions; further studies revealed that tyrosine kinase and protein 
kinase A (PKA) were involved since their respective inhibitors genistein and H89 
strongly inhibited the acti-contractile effect of periadventitial adipose tissue 
(Dubrovska et al., 2004). 
1.2.3.3. Proposed mechanisms explaining the anti-contractile effect mediated 
by ADRF 
Although little evidence is available for both the physical and chemical 
nature of the hypothesized ADRF, researchers work hard in order to gather every 
pieces of information available, hoping to reveal the secret behind. 
Since ADRF has not been identified or isolated, it is reasonable to suspect 
- 1 7 -
that ADRF may be a "group" instead of a single molecule (Gollasch and Dubrovska, 
2004)，because tyrosine kinase and PKA can mediate many cytosolic events which 
will finally cause the release of vasoactive substances (Lohn et al.，2002; Gollasch 
and Dubrovska, 2004; Ahmed and Eickholt, 2007; Fetalvero et al., 2007). However, 
the signal transduction cascade mediated by ADRF can still be determined even 
without knowing its nature, and it definitely can provide useful information for the 
identification of the chemical nature of ADRF. 
One piece of important information comes from a study of Lohn et ai, in 
which the anti-contractile effect of periadventitial fat is still present in the Zucker fa/fa 
rats, suggesting that leptin receptors are not involved in ADRF-dependent signal 
transduction pathways (Lohn et al., 2002), thus eliminating the possibility that leptin 
is ADRF. 
The most important and inspiring pieces of information concerning the 
mechanisms behind the action of ADRF come form the abolishment of its effect in 60 
mM K+-containing saline solution. The anti-contractile effect of periadventitial fat 
disappears when the blood vessel is depolarized by 60 mM K+ (Lohn et al, 2002; 
Dubrovska et al., 2004; Gollasch and Dubrovska, 2004; Verlohren et al, 2004; Gao et 
al., 2005). These results indicate that the periadventitial adipose does not impose 
physical hindrance to isolated blood vessel bathed in saline solution. In addition, the 
authors also indicated that either closure of K+ channels or strong depolarization can 
eliminate the effect of ADRF-like factors. 
This idea of an involvement of K+ channels is examined using various 
blockers of different K+ channels subtypes. It is found that different subtypes of K+ 
channels are involved in the anti-contractile effect of periadventitial adipose tissue in 
different isolated arteries. For example, the action of ADRF can be blocked by 
glibenclamide in Sprague-Dawley rat aortas, implying that the ATP-dependent (KATP) 
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K+ channels may be involved (Lohn et al., 2002). But in the rat mesenteric arteries, 
the voltage-dependent, delayed-rectifier K+ (Kv) channels appear to play an important 
role since the effect of ADRF is inhibited or even abolished by 4-aminopyridine and 
3,4-diaminopyri(iine (Verlohren et al, 2004). On the other hand, Gao et al. show that 
in human internal thoracic arteries, the anti-contractile action of ADRF is mainly 
mediated by large-conductance, Ca^'^-activated K+ (BKca) channels because blockade 
of this channel by tetraehylammonium or iberiotoxin reduces the effect of ADRF 
(Gao et al., 2005). The above-described studies support the hypothesis that 
ADRP-like factors could cause membrane hyperpolerization probably by direct or 
indirect opening of different types of K+ channels depending on the species and 
anatomical locations of blood vessels dissected for investigation. Direct measurement 
of the membrane potential of artery segments with/without periadventitial adipose 
tissue further supports this hypothesis (Verlohren et al.’ 2004). 
Apart from the contribution of K+ channels, other hypotheses are also 
proposed. Although previous studies showed that the endothelium is unlikely to be 
involved in the action of ADRF (L5hn et al., 2002; Verlohren et al” 2004), Gao et al. 
provided a different set of results. In their study, using donor-recipient bioassay, the 
relaxation caused by bathing solution from Wistar rat arteries containing periadvential 
fat can be abolished by the removal of endothelium, nitric oxide synthase inhibition 
and nitric oxide scavenger (Gao et al, 2007). In addition, the anti-contractile effect of 
periadventitial fat is reduced by the soluble guanylyl cyclase inhibitor. In contrast, the 
anti-contractile effect can be further enhanced by superoxide dismutase and tiron (Gao 
et aL, 2007). These findings suggest that the action of ADRF which involves the 
activation of soluble guanylyl cyclase and H2O2. 
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1.2.4. Objectives of current study 
Above-mentioned studies concern only the effect of the periadventital adipose 
tissue on vasoconstriction and no study has ever tried to link the periadvential 
adipose tissue to vaso-relaxation caused by vaso-relaxants. In view of that the 
thromboxane A2 receptor activation can cause inhibition of vaso-relaxation triggered 
by various nitric-oxide-dependent dilators (Streefkerk et al” 2002), it will be 
important to examine whether such inhibition can be affected by the presence of 
periadventitial fat. 
Using isolated aortas from the female Wistar rats, this study aims to determine 
whether the inhibition of vasorelaxation caused by U46619, a thromboxane A2 
receptor agonist, can be affected by the presence of periadvential adipose tissues, and 




2.1. Tissue Preparation 
2.1.1. Preparation of blood vessels 
A approval of the Animal Research Ethics Committee of the Chinese University 
of Hong Kong was obtained for all the experiments described in this thesis. All the 
procedures followed the Guide for the Care and Use of Laboratory Animals published 
by the US national institute of Health (NIH publication No. 85-23, revised 1996). 
Female Wistar rats (240g - 250g), were used in the present study and they were 
supplied by the Laboratory Animal Services Center, the Chinese University of Hong 
Kong, Hong Kong SAR, China. 
The female Wistar rats were sacrificed by inhaling 95% CO2. The rat thoracic 
aorta was carefully dissected out and immediately immersed in a freshly-prepared, 4 
Krebs-Henseleit solution (composition listed in table 2.4B. of this section) which 
were oxygenated with 95% O2 plus 5% CO2. The connective tissue surrounding the 
rat thoracic aorta was removed under a dissection microscope. In some arterial tissues, 
the periadventitial fat was left intact. The artery was then cut into in segments with 
approximately 3-4 mm in length. 
2.1.2. Procedures to remove the endothelium 
The endothelium of aortic rings was mechanically removed by carefully 
rubbing the luminal surface of the ring against a pair of forceps. Functional removal 
of the endothelial layer was confirmed by elimination of a relaxant response to 1 
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acetylcholine (ACh) after pre-contraction by 3 jiM phenylephrine. 
2.2. The Organ Bath Setups 
Each arterial ring was suspended between two stainless steel pins (100 )j,m 
indiameter) bathing in a transparent, plastic organ bath. The organ bath was filled with 
10-ml Krebs-Henseleit solution which was continuously bubbled with a gas mixture 
of 95% CO2 - 5% O2 and maintained at 37C, giving a pH of 7.3-7.4. The upper pin 
was connected to a force transducer (FT-03, Grass Instruments Co., Quincy, MA, 
USA) via a surgical wire (non sterilized). The lower pin was stabilized by the 
supporting device of the organ bath. The force transducer was connected to a 
PowerLaBMSP data recording device (ADinstruments Corporate), accompanied with 
the Maclab software (version 4.0) and a Mac computer, the changes in tension were 
continuously recorded. A complete setup is illustrated at Fig. 2.2A. 
Each arterial ring was placed under an initial tension of 2.5g, which was the 
optimum tension determined by length-tension relationships. The rings were then 
allowed to equilibrate for 30 min. After the equilibration period, the rings were first 
challenged with 60 mM K+ Kerbs-Henseleit solution in order to test their viability. 
Rings which produced lesser then Ig of tension in 60 mM K+ solution were discarded. 
Intactness or removal of a function endothelium was then verified using the method 
described at section 2.1.2. 
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Bubbling with S —— 
- - W 1 
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— I — 
(i) (ii) 
Fig 2.2A. (i) Actual photo of the organ bath setup, (ii) Schematic graph 
for an organ bath setup 
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2.2. Calculation of Results 
2.2.1. Calculation of active tension 
The changes in isometric tension were expressed in active tension for all the 
experiments. The active tension was calculated by dividing the changes of tension by 
the dry mass of the arterial rings. The unit of the active tension is g/mg'^. 
2.2.2. Measurement of dry weight of arterial rings 
By the end of each experiment, the arterials rings were removed and placed in 
an oven maintained at 50 °C for 10 hours, and then subjected to an electronic scale for 
dry weight measurement. 
In experiments involving rings with the periadventitial fat, the surrounding fat 
was carefully removed before starting the tissue drying procedure. 
2.2.3. Measurement of the weight for periadventitial fat 
The periadventital fat was carefully removed from the arterial rings, and then 
dried in room temperature for 24 hours before weighing in electronic scale. 
2.2.4. Statistic analysis 
Paired and unpaired Student t tests or ANOVA were used as appropriate. A P 
value<0.05 was considered statistically significant. All values were presented as 
mean士SEM. All experiments were repeated on rings for at least 4 different rats. 
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2.3. Chemicals and Solutions 
2.3.1. Chemicals 
Chemicals used in the experiments are listed in table 2.4A. Usages of these 
chemicals were approved by the Safety Office, the Chinese University of Hong Kong, 
Hong Kong SAR, China. 
Table 2.4A. Chemicals 
Chemicals Description Solvent Supplier 
Acetylcholine hydrochloride Muscarinic Nano-water Tocris 
(ACh) receptor agonist 
9,11-Dideoxy-lla, Thromboxane A2 DMSO Sigma 
9a-epoxymethano-prostaglandin receptor agonist 
Fza (U46619) 
Dimethyl sulphoxide (DMSO) Organic solvent ~ Sigma 
Hydroxylamine Exogenous nitric Nano-water Sigma 
oxide donor 
3-Isobutyl-1 -methylxanthine Phosphodiesterase DMSO Sigma 
(IBMX) inhibitor 
Morpholinosydnonimine Exogenous nitric Nano-water Sigma 
(SIN-1), oxide donor 
Phenylephrine HCL (Phe) ai- Nano-water Sigma 
adrenoreceptor 
agonist 
SI8886 Tliroboxane A2 Nano-water Sigma 
receptor 
antagonist 
Sodium nitroprusside (SNP) Exogenous nitric Nano-water Sigma 
oxide donor 




Compositions of the solutions used are listed in table 2.4B. All of the solutions 
were freshly prepared before each experiment. 
Table 2.4B. Composition of Solutions 
Chemicals Krebs Henseleit (mM) 20/60 mM K+ 
Krebs Henseleit (mM) 
D-glucose 11.10 11.10 
NaCl 119.00 103.00/63.00 
NaHCOs 25.00 25.00 
MgCl2'6H20 
KCl 4.70 20.00/60.00 
KH2PO4 
CaClz ^ ^ 
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CHAPTER III 
Stimulation of TP receptors by U46619 inhibits 
cGMP dependent vaso-relaxation 
3.1. Detail methods and materials 
3.1.1. Safety announcement, tissue preparation and materials 
All the safety announcement, tissue preparation and materials are listed in 
Section 2 of this thesis. 
3.1.1. Protocol 
The general protocol is the same for all sets of experiments described in this 
thesis. This section provides only detailed experiment procedures. 
3.1.1.1. Part I 
In the first series of the experiments, aortic rings with and without the 
endothelium were exposed to different concentrations of U46619 (10, 30 and 100 nM) 
prior to being relaxed by endothelium-dependent vasodilator, acetycholine (ACh, 3 
nM - 10 }iM) in rings with the endothelium, and to endothelium-independent 
vasodilators such as sodium nitroprusside (SNP, 3 nM - 10 |iM), hydroxylamine (3 
nM - 100 \xM} and SIN-1 (3 nM - 30 i^M) in rings without the endothelium. These 
experiments were repeated using 3 |iM phenylephrine (Phe) to contract the aortic 
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rings as control. 
3.1.1.2. Part II 
In the second group of the experiments, the aortic rings were constricted with 
300 nM of U46619. Y27632 (2 jiM for rings with endothelium, 4 i^M for rings 
without endothelium) and IBMX (5 |iM for rings with endothelium, 20 |iM for rings 
without endothelium) were added to the bathing solution once a stable tension was 
developed. Concentration-response relaxation to ACh or SNP (3 nM — 10 |iM) was 
obtained 15 min after the addition of Y27632 and IBMX. 
3.1.1.3. Part III 
In the third set of the experiments, the aortic rings were first contracted by 3 
\iM phenyephrine; then relaxed by cumulative additions of ACh in endothelium-intact 
rings, and by SNP in endothelium-denuded rings. After washout away of ACh or SNP, 
the rings were subjected to the following 15-min treatments: (1) control, (2) 3 nM 
U46619, (3) 0.3 ^M S18886, (4) 3 nM U46619 + 0.3 |iM S18886，(5) 3 nM U46619 + 
0.5 ^iM Y27632, and (6) 3 nM U46619 + 1 |iM IBMX, before contraction by 
phenylephrine again. Thereafter, another concentration-response curve to ACh or SNP 
(3 nM 一 10 jiM) was repeated. 
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3.2. Results 
3.2.1. Effect of U46619 on vaso-relaxation 
In isolated rat aortas contracted by U46619 (10，30 and 100 nM), the 
relaxations induced by ACh (3 nM - 10 |iM) in endothelium-intact rings were 
significantly attenuated (Fig. 3.2.A.) in a concentration-dependent maimer. Similar 
results were obtained in aortic rings without endothelium using SNP (3 nM - 10 |iM), 
hydroxylamine ( 3 n M - l mM), or SIN-1 (3 nM - 30 i^M) (Fig. 3.2. and Fig.3.3.)-
3.2.2. Effect of Rho kinase and phosphodiesterase inhibitor on the inhibitory 
effect ofU46619 
Under the stimulation of 300 nM U46619, similar inhibitory on ACh and SNP 
induced vaso-relaxation on both rings with and without endothelium was observed. 
Such inhibitory effect was reversed by treatment with 2 ^M of Rho kinase inhibitor 
Y27632and 5 \iM of phosphodiesterase inhibitor IBMX in endothelium intact rings 
(Fig. 3.4. A.) In endothelium removed rings, inhibitory effect to vaso-relaxation 
caused by U46619 was abolished by 4 |iM of Y27632 and 20 ^M of IBMX (Fig. 
3.4.B.). 
3.2.3. The effect of low concentration of U46619 on vaso-relaxation 
Low concentration of U46619 (3 nM) normally could not cause detectible 
contraction. 3 |iM of phenylephrine was added together with 3 iiM U46619 in order to 
examine the effect of TP receptor stimulation on nitric oxide-mediated vasorelaxation. 
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Low concentration of U46619 produced a significant inhibition of vaso-relaxation in 
response to ACh in endothelium-intact rings or to SNP in endothelium removed rings 
(Fig. 3.5.A. and 3.5.B.). The degree of inhibitory effect produced by 3 nM U46619 
was smaller in endothelium removed rings. The inhibitory effect of U46619 was 
reversed by the treatment with 0.5 |iM Y27632. There was no control experiment in 
Fig. 3.5.A., which supposed to incubate the aortic rings with 0.5 [lM Y27632. 
However, 0.5 |xM Y27632 alone inhibited the vaso-contraction induced by 
phenylephrine, so no sustained tension can be obtained in the presence of 0.5 }iM 
Y27632. 
The inhibitory effect of 3 nM U46619 on vaso-relaxation induced by ACh in 
endothelium intact rings and by SNP in endothelium removed rings was abolished by 
0.3 i^M S18886 (Fig. 3.6.A. and 3.6.B.). In control experiments, 0.3 i^M S18886 
caused no significant changes on vaso-relaxation. 
The inhibitory effect of 3 nM U46619 on vaso-relaxation induced by ACh 
endothelium intact rings and by SNP in endothelium removed rings was also 
abolished by 1 i^M IBMX (Fig. 3.7.A. and 3.7.B.). 1 i^M IBMX alone did not 
significantly alter the vaso-relaxation in endothelium intact and denuded rings in 
response to ACh and SNP. 
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Fig. 3.2. Concentration-response curve to relaxation triggered by ACh (A) 
in rings with endothelium and SNP (B) in rings without endothelium. 
U46619 inhibited the relaxation induced by both ACh and SNP in a 
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Fig. 3.3. Concentration-response curve to the relaxation triggered by 
hydroxylamine (A) and SIN-1 (B) in aortic rings without endothelium. 
U46619 inhibited the relaxation induced by both hydroxylamine and SIN 
-1 in a concentration-dependent manner. Data are expressed in mean 土 
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Fig. 3.4. Concentration-dependent relaxation by ACh in rings with 
endothelium and SNP in rings without endothelium, contracted by 300 
nM U46619. The inhibitory effect of U46619 was reversed by 2 [M 
Y27632 (Rho kinase inhibitor) and 5 |iM IBMX (phophodiesterase 
inhibitor) in rings with endothelium (A) and in rings without endothelium 
(B). Similar results was obtained in 4 \xM Y27632 and 20 |iM IBMX. 
Data are expressed in mean 士 SEM of 6-20 experiments. 
-33-
A §100] 
一 -O-Cont ro l 
^ 5 0 - ^ g r """"^ " • " i n c u b a t e d with 3 nM 
C L ^ t ^ T X U46619 
B 1 - ^ 3 n M U 4 6 6 1 9 + 0.5 |iM 
^ 丫27632 
0 � 
I 1 1 1 1 
- 9 - 8 - 7 - 6 - 5 
ACh (log M) 
B 
• g 1 0 0 - 1 - O - C o n t r o l 
O - • - i n c u b a t e d with 3 nM U46619 
一 - 0 - 0 . 5 | ^ M Y27632 
^ 5 Q . - * - 3 n M U46619 + 0.5 [M Y27632 
^ � ^ ^ ^ 
u � 
I 1 1 1 r 
- 9 - 8 - 7 - 6 - 5 
SNP (log M) 
Fig. 3.5. Rho kinase inhibition induced by Y27632 reduced the 
anti-relaxation effect of 3 nM U46669 on relaxation induced by ACh in 
rings with endothelium (A) and by SNP in rings without endothelium (B). 
Data are expressed in mean 土 SEM of 6-23 experiments 
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Fig. 3.6. Treatment with 0.3 [iM SI8886 abolished the inhibitory effect of 
3 nM U46619 on vaso-relaxation in response to ACh in rings with 
endothelium and to SNP in rings without endothelium. Data are expressed 
in mean 士 SEM of 6-12 experiments. 
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Fig. 3.7. 1 |iM IBMX (phosphodiesterase inhibitor) abolished the 
anti-relaxant effect of 3 nM U46619 on relaxation induced by ACh in 
rings with endothelium (A) and by SNP in rings without endothelium (B). 
Data are expressed in mean 士 SEM of 4-6 experiments. 
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3.3. Discussion 
3.3.1. Implication of the current study 
Fig. 3.2.A. shows that U46619 concentration-dependently inhibits the 
vaso-relaxation induced by ACh in endothelium intact rings. The inhibitory effect of 
U46619 is also observed on relaxation induced by nitric oxide donor, SNP in 
endothelium denuded aortic rings. The results suggest that endothelium is not 
involved in the anti-relaxant effect of U46619. These findings confirm the results 
provided by Streefkerk et al (Streefkerk et al, 2002). 
The first idea raised up after obtaining afore-mentioned data is that U46619, or 
the activation of the TP receptor, may interfere with the nitric oxide metabolic 
pathway. However, although SNP is commonly used as exogenous nitric oxide donor, 
SNP is also reported to exert a non-nitric oxide related effect on various tissues 
(Akopova et al., 2003). In order to eliminate the possibility that the observed 
difference is caused by nitric oxide-independent effect of SNP, two additional 
exogenous nitric oxide donors, hydroxylamine and SIN-I, were employed with the 
same protocol. Fig. 3.2.B. shows that U46619 exerts a comparable inhibitory effect to 
vaso-relaxation in response to hydroxylamine and SIN-1. Our findings strongly 
support that nitric oxide-independent action of SNP (if such an action exists) is 
unlikely to be involved in the anti-relaxant effect of U46619. In addition, such 
anti-relaxant effect is independent of the source of nitric oxide (endogenous or 
exogenous) and the presence or absence of the endothelium. 
We next went to examine the possible mechanisms that mediate the 
anti-relaxant effect of U46619. As discussed above, the role of the intermediates in 
the nitric oxide pathway, and probable molecules involved in the signal transduction 
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cascade following stimulation of the TP receptor were first investigated. U46619 at 
300 nM is used in order to achieve the best resolution of the results, since contraction 
by this concentration almost prevents cyclic GMP-dependent vaso-relaxation 
(Streefkerk et al., 2002). As shown in Fig. 3.4.A.，the relaxant response to ACh in the 
presence of U46619 is fully restored by the treatment with 2 |iM Y27632, the 
Rho-associated kinase (ROK) inhibitor or with 5 |aM IBMX, the phosphodiesterase 
inhibitor in the endothelium intact rings. In aortic rings without the endothelium, the 
relaxing effect of SNP in the presence of U46619 is restored by the treatment with 4 
|iM Y27632 or with 20 jiM IBMX. This set of data indicates that there are two groups 
of hypothetical targets, ROK and phosphodiesterases, which can explain the 
anti-relaxant effect of U46619 on nitric oxide-dependent vaso-relaxation. According 
to published studies, the signal transduction cascade due to the activation of the TP 
receptor is still not fully understood. However, ROK is reported to be one of the major 
members along the pathway (Velasco et al., 2002; Sw^d et al., 2003). In addition, 
phosphodiesterases are the major group of enzymes that break down both cyclic AMP 
and cyclic GMP; both intracellular messengers lead to vaso-relaxation. Especially for 
cyclic GMP, it is the major signaling molecule involved in the nitric oxide-mediated 
vaso-relaxation. The difference in concentration of Y27632 and IBMX used for 
endothelium intact and removed rings is mainly due to technical concerns. In the 
actual experiments, after the addition of Y27632 or IBMX, the vascular tone drops 
slightly. And in aortic rings with a functional endothelium, the drop in vascular tone is 
greater than that of rings without endothelium. As a result, an adjustment to the 
concentration of Y27632 and IBMX is necessary in order to achieve similar 
amplitudes of vascular tension of rings with and without endothelium. This is why the 
higher concentration of Y27632 and IBMX is used in aortic rings without 
endothelium. 
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Until now, U46619 is regarded as a specific TP receptor agonist (Mayeux et al., 
1988，1991) and no non-specific effect has been reported. However, the possibility for 
the presence of non-specific effect can not be discounted. In addition, the high 
concentrations of U46619 were used in the current study which, if converted to the 
concentration of thromboxane A2, will never be achieved under physiological 
conditions (Fitzgerald et al., 1983; Lellouche et al., 1990). So the next set of 
experiments were designed to confirm: (1) whether the anti-relaxant effect of U46619 
is mediated by the TP receptor and (2) whether this anti-relaxant effect is still 
observable when the concentration of the TP receptor agonist is lowered. U46619 at 3 
nM, a concentration that normally does not trigger any vaso-contraction in aortic rings, 
are used to incubate the arterial tissues. Since there is no vaso-contraction in response 
to 3 nM U46619, 3 pM phenylephrine is added to produce an increase in vascular 
tone which is needed for relaxation studies. This concentration of phenylephrine is 
proven to have no significant effect on vaso-relaxation triggered by a wide group of 
vasorelaxants in aortas (Streefkerk et al., 2002). 
Endothelium intact vessel rings exposed to 3 nM U46619 displays a significant 
reduction in vaso-relaxation in response to ACh as shown in Fig. 3.5.A. Our results 
clearly show that even at a low concentration of the TP receptor agonist, which has no 
effect on basal vascular tone, the inhibitory effect on ACh-induced vaso-relaxation is 
evident. Likewise, treatment with 3 nM U46619 also inhibits 
endothelium-independent relaxation to SNP in rings without endothelium as shown in 
Fig. 3.5.B. Besides, the presence of 0.5 ^M Y27632 abolishes the anti-relaxant effect 
of U46619 in rings with and without endothelium (Fig. 3.5.A. & 3.5.B.). These results 
suggest that ROK may play a key role in the inhibitory effect of U46619. There is no 
experiment with incubation of aortic rings with 0.5 |iM Y27632, to test whether 
Y27632 at this concentration could affect evoked relaxation in 
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phenylephrine-contracted rings. In endothelium intact rings, incubation of 0.5 |iM 
Y27632 alone abolishes the vaso-constriction. But this inhibitory effect diminishes 
with the presence of 3 nM U46619 and in rings without endothelium; the reasons 
behind are out of the scope of the current study. It is documented that inhibition of 
ROK by Y27632 can inhibit the adrenoceptor activation-associated cellular processes 
(Suematsu et al, 2001; Roberts, 2004), which may explain the anti-contractile effect 
of this agent on contraction induced by the adrenoceptor agonist. 
However, the next question will be whether the inhibitory effect of U46619 on 
nitric oxide-dependent relaxation is mediated through the TP receptors. The next set 
of experiments is designed to answer this question. First, a TP receptor specific 
antagonist, SI8886，is used. In the endothelium intact rings, the inhibitory effect of 3 
nM U46619 on vaso-relaxation induced by ACh is eliminated by the incubation of 0.3 
ILM S18886 as shown in Fig. 3.6.A. Similar effect for S18886 is also observed in 
aortic rings without a functional endothelium where SNP is used as nitric 
oxide-dependent dilator as demonstrated in Fig. 3.6.B. Since S18886 is a highly 
specific TP receptor antagonist (Simonet et al., 1997; Gaussem et al, 2005), the 
removal of the anti-relaxant effect by SI8886 clearly supports the hypothesis that 
such an effect of U46619 is mediated through the TP receptor. In addition, SI8886 
alone has little to no effect on contraction triggered by phenylephrine in the same 
arterial preparations, thus confirming the specificity of this antagonist (Fig. 3.6.A & 
3.6.B). Furthermore, the treatment with SI8886 alone does not influence the 
vaso-relaxation induced by ACh in endothelium intact rings. This effect of SI8886 
may explain its use for the improvement of endothelial function (Belhassen et al, 
2003). 
Finally, the involvement of phosphodiesterases in the anti-relaxant effect 
mediated by the TP receptor is discussed. Incubation of 1 |iM IBMX, the 
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phosphodiesterases inhibitor prevents the inhibitory effect of 3 nM U46619 on 
relaxation in response to ACh in rings with endothelium as shown in Fig. 3.7.A. 
Similar observations are made on the endothelium-independent relaxation to SNP in 
the presence of 3 nm U46619 (Fig. 3.7.B). 
IBMX is quite a non-specific phosphodiesterase inhibitor (Beavo et al., 1971) 
and it inhibits both cAMP and cGMP phosphodiesterases and their respective 
subtypes. Therefore, the results obtained in this study can only be regarded as a 
preliminary test as to the possible role of phosphodiesterases. From the data shown in 
Fig. 3.7.A. & 3.7.B, the inhibition of phosphodiesterases by IBMX can eliminate the 
anti-relaxant effect of the TP receptor activation. If the activity of phosphodiesterases 
is inhibited by IBMX, the bioavailability of cyclic AMP or cyclic GMP, both causing 
vasodilatation, would be significantly increased. It is reasonable to deduce that the 
stimulation of phosphodiesterases may be one of the possible downstream 
mechanisms secondary to the TP receptor activation. However, the functional study 
can only provide indirect evidence, direct measurement of cyclic AMP or cyclic GMP 
is required in order to give a direct support of the hypothesis that the activation of 
phosphodiesterases is involved in U46619-induced inhibition of nitric 
oxide-dependent vasorelaxation. 
3.3.2. Formulated Theory 
From the data available in this study, an overall hypothetical picture concerning 
the anti-relaxation caused by the activation of TP receptors is formulated. When the 
TP receptors are activated in aortas of female Wistar rats, subsequent stimulation of 
ROK will cause an increase in activity of phosphodiesterases, which in turn results in 
reduced levels of intracellular cyclic AMP and/or cyclic GMP, thus responsible for the 
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impaired relaxing responses to nitric oxide/cyclic GMP-dependent vaso-dilators such 
as A C h and SNP. 
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CHAPTER IV 
Effect of periadventitial fat on anti-relaxation effect 
induced by U46619 一 A preliminary test 
4.1. Detail methods and materials 
4.1.1. Safety announcement, tissue preparation and materials 
All the safety announcement, tissue preparation and materials are listed in 
Section 2 of this thesis. 
4.1.2. Protocol 
The general protocol shared by all set of experiments is listed in Section 2 of 
this thesis. In this section, only detailed experiment procedures after the general 
protocol will be included. 
4.1.2.1. Part I 
At the first part of the experiments, aortic rings with and without endothelium 
were exposed to 3 ^M phenylephrine, then relaxed by ACh (3 nM - 10 |iM) for rings 
with endothelium and SNP (3 nM - 10 i^M) for rings without endothelium. These 
experiments were repeated in aortic rings with periadventitial fat attached. 
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4.1.2.2. Part II 
In this set of experiments, aortic rings with and without endothelium were first 
constricted by 3 ^iM phenylephrine plus 30 nM U46619, then relaxed by ACh (3 n M -
10 |iM) for rings with endothelium and SNP (3 nM - 10 |iM) for rings without 
endothelium. These experiments were also repeated in artery rings with 
periadventitial fat attached. 
4.1.2.3. Part III 
In aortic rings without endothelium, the rings were first incubated with 0.3 |iM 
SI8886，followed by contraction by 3 |iM phenylephrine plus 30 nM U46619. Once 
stable tension was developed, the rings were relaxed by SNP (3 nM - 10 |iM). The 
experiment was repeated in rings with periadventitial fat attached. 
4.1.2.4. Part IV 
The aortic rings with and without periadventitial fat were treated with 20 mM 
K+ containing Krebs solution, then contracted with 3 i^M phenylephrine plus 30 nM 
U46619 and subsequently relaxed by ACh (3 nM - 10 jiM) in rings with intact 
endothelium and SNP (3 nM - 10 |iM) in rings with endothelium removed. The 
experiment was repeated by replacing 20 mM K+ with 60 mM K+ containing Krebs 
solution. 
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4.2. Results 
4.2.1. Effect of periadventitial fat on vaso-relaxation of rings contracted by 
phenylephrine 
In vessels contracted by 3 |iM phenylephrine, periadventitial fat did not affect 
the vasodilation induced by ACh (3 nM - 10 jiM) in endothelium intact rings (Fig. 
4.1.). Same results were also obtained in endothelium removed rings where SNP (3 
nM - 10 jj-M) was used to induce vaso-relaxation (Fig. 4.2.). 
4.2.2. Effect of periadventitial fat on vaso-relaxation of rings contracted by 
U46619 plus phenylephrine 
The vaso-relaxation induced by ACh (3 nM - 10 |JM) was abolished when 30 
nM U46619 plus 3 jiM phenylephrine were used as vasoconstrictors in endothelium 
intact rings. Periadventitial fat had no significant effect on the lack of relaxation to 
ACh (Fig. 4.3.). However, in endothelium removed rings where SNP (3 nM - 10 |iM) 
was used to relax the vessel, the rings with periadventitial fat attached showed a 
significant increase in vaso-relaxation with high concentrations of SNP (Fig. 4.4.). 
4.2.3. Effect of S18886 on vaso-relaxation in endothelium removed rings 
The anti-relaxation effect caused by 30 nM U46619 plus 3 |iM phenylephrine 
was completely prevented by 0.3 |iM S18886 (the selective TP receptor antagonist) in 
endothelium removed rings when SNP (3 nM - 10 i^M) was used to relax the aortic 
rings (Fig. 4.5.). 
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4.2.4. Effect of elevated extracellular potassium ions on vaso-relaxation 
In endothelium intact aortic rings, both 20 mM K+ and 60 mM K+ containing 
Krebs solution completely abolished the vaso-relaxation induced by ACh (3 nM - 10 
|j,M) in contraction by 30 nM U46619 plus 3 |iM phenylephrine, and the presence of 
periadventitial fat did not have any observable effect on the lack of relaxation to ACh 
(Fig. 4.6.A. and 4.6.B.) 
In endothelium removed aortic rings, 20 mM K^-containing Krebs solution 
partially reduced the increased vaso-relaxation in rings with periadventitial fat 
attached (Fig. 4.7.A.)’ where SNP (3 nM - 10 i^M) was used to relax the aortic rings. 
In 60 mM K+ condition, the vaso-relaxation induced by the same concentration range 
of SNP was abolished and periadventitial fat did not have any effect on this ionic 
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Fig 4.1. Lack of the influence of the presence of periadventitial fat on the 
vaso-relaxation induced by ACh in endothelium intact rings. 
Acetylcholine was added cumulatively once a steady contraction was 
induced by phenylephrine. Data are expressed in mean 士 SEM of 6 
experiments. 
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Fig 4.2. The presence of periadventitial fat dose not statistically reduce 
the vaso-relaxation induced by sodium nitroprusside (SNP) in 
endothelium removed rings. Data are expressed in mean 土 SEM of 4-5 
experments. 
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Fig. 4.3. Vaso-relaxation induced by ACh was abolished in 
endothelium-intact aortic rings contracted by simultaneous application of 
30 nM U46619 plus 3 [iM phenylephrine and lack of effect of the 
presence of periadventitial fat on such inhibition. Data are expressed in 
mean 土 SEM. 
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Fig. 4.4. Vaso-relaxation induced by SNP was significantly enhanced in 
aortic rings with periadventitial fat attached when arteries were 
contracted by 30 nM U46619 and 3 |iM phenylephrine. Data are 
expressed in mean 土 SEM of 7 experiments. Significant differences are 
indicated by * with P < 0.05. 
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Fig. 4.5. The anti-relaxant effect caused by 30 nM U46619 plus 3 |iM 
phenylephrine on SNP-induced relaxation was abolished by 0.3 |JM 
SI8886 in endothelium removed rings. Data are expressed in mean 土 
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Fig. 4.6.A. Bathing in 20 mM K+-containing Krebs solution abolish the 
vaso-relaxation induced by ACh in endothelium intact rings and the 
presence of periadventitial fat had no effect on the inhibition. Arteries 
were pre-contracted by 30 nM U46619 plus 3 [iM phenylephrine. Data 
are expressed in mean 土 SEM of 6 experiments. 
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Fig. 4.6.B. Bathing in 60 mM K+-containing Krebs solution abolish the 
vaso-relaxation induced by ACh in endothelium intact rings and the 
presence of periadventitial fat had no effect on the inhibition. Arteries 
were pre-contracted by 30 nM U46619 plus 3 jiM phenylephrine. Data 
are expressed in mean 土 SEM of 6 experiments. 
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Fig. 4.7.A. Bathing in 20 mM K+-containing Krebs solution partially 
reduced the increased vaso-relaxation in the presence of periadventitial 
fat in endothelium removed vessel rings where SNP was used as 
vaso-relaxant. Arteries were pre-contracted by 30 nM U46619 plus 3 |iM 
phenylephrine. Data are expressed in mean 土 SEM of 6 experiments. 
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Fig. 4.7.B. Bathing in 60 mM K+-containing Krebs solution completely 
abolished the increased vaso-relaxation in the presence of periadventitial 
fat in endothelium removed vessel rings where SNP was used as 
vaso-relaxant. Arteries were pre-contracted by 30 nM U46619 plus 3 |iM 
phenylephrine. Data are expressed in mean 土 SEM of 4-5 experiments. 
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4.3. Discussion 
4.3.1. Implication of current study 
Although there are many studies concerning the anti-contractile effect of 
periadventitial fat (references refer to the section 1.2.)，no studies have discussed the 
influence of periadventitial fat on vaso-relaxation. We wanted to examine whether 
vaso-relaxation can be affected by periadventitial adipose tissue. As shown in Fig. 4.2., 
the presence of periadventitial fat does not impact on vaso-relaxation caused by ACh 
in endothelium-intact aortic rings, while the surrounding adipose tissue slightly 
reduced endothelium-independent relaxation to SNP in endothelium removed rings 
(Fig. 4.3.) These results suggest that adipose tissue surrounding the arteries may play 
a minor role in the modulation of nitric oxide-mediated relaxation. 
Another part of the experiments was designed to investigate the relationship 
between periadventitial fat and U46619-induced anti-relaxant effect. In 
endothelium-intact rings, the presence of periadventitial fat had no effect on 
contraction triggered by U46619 plus phenylephrine. On the contrary, the relaxation 
to SNP at high concentrations is increased in rings without a functional endothelium 
as shown in Fig. 4.5. Gao et al. have recently proposed that the removal of 
endothelium abolished the anti-contractile effect of periadventitial fat (Gao et al, 
2007). The present results are somehow consistent with the study, but show some 
differences. What is similar is the involvement of endothelium in periadventitial 
fat-arterial tone modulation process. What is different is that in our result, removal of 
endothelium enhances, but not reduces, the relaxation of arteries. Because both 
studies used Wistar rat aorta, the possibility for the special variation to cause such 
difference is low. The most possible explanation is that ADRF may trigger different 
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signal transduction processes in response to contraction and relaxation which has not 
been proposed before. Further studies are needed to verify this hypothesis. 
At this point, the focus is mainly on the relaxation-enhancing ability of 
periadventitial fat to SNP in endothelium-denude aortic rings. Following the same 
route of reasoning, it is always important to check whether the effect is mediated by 
the activation of TP receptor or by a non-specific effect of U46619. A highly specific 
TP receptor blocker, S18886 abolished the anti-relaxant effect of 30 nM U46619 (Fig. 
4.6.). However, the presence of periadventital adipose tissue shows a small inhibitory 
effect. The present results suggest that (1) the TP receptors activation can inhibit the 
SNP-induced vaso-relaxation, and (2) such anti-relaxant effect may be partially 
reduced by periadventitial adipose tissue. 
The present study attempted to investigate the mechanisms behind the 
relaxation-enhancing ability of periadventitial fat upon stimulation of the TP receptor. 
As mentioned in the chapter 1.2., K+ channels are the major hypothetical targets for 
the action of ADRF. The fastest way to evaluate whether the opening of K+ channels 
is involved in the modulation of vascular tone is to challenge the aortic rings with a 
moderate to high level of extracellular potassium ions since elevated extracellular 
potassium will disable all K+ channels by narrowing the electrochemical gradient for 
potassium efflux. As shown in Figure 4.8.A.，20 mM external K+ partially attenuated 
the relaxation-enhancing ability of periadventitial fat under stimulation of the TP 
receptor in endothelium-denuded aortic rings. When the external K+ concentration is 
raised to 60 mM, the relaxation responses, including the effect of periadvential fat, are 
abolished (Fig. 4.8.B). This implies that membrane depolarization in VSM can abolish 
the vaso-relaxation induced by SNP and also the relaxation-enhancing effect of 
periadventitial fat when the TP receptor is activated. The lack of relaxant response in 
endothelium intact rings in 20 mM and 60 mM K+-containing bathing solution (Fig. 
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4.7.A. and 4.7.B.) is consistent with the results shown in Fig. 4.4. 
4.3.2. Improvements and future perspectives of current study 
This is the first study concerning the effect of periadventitial adipose tissue on 
vaso-relaxation, the results are rather preliminary. One of the routes for further 
investigation is to identify the types of K+ channels that may be involved using 
specific K+ channel subtype blockers, which will give us a clearer picture of the 
impact of periadventitial adipose tissue on the modulation of vasorelaxation, and will 
probably give us additional hints leading to reveal the identity of ADRF. In addition, it 
is important to check if there are TP receptors expressed in the periadventitial adipose 
tissues since the information on TP receptors may also provide us with clues to 
deduce whether direct activation of the TP receptor in cells within adipose tissue plays 
a physiological role in modulating arterial tone. 
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Summary 
The results of the current studies are summarized as following four points: 
1. Activation of the TP receptor can inhibit the cyclic GMP-dependent 
vaso-relaxation in rat aortas. 
2. Indirect evidence shows that the inhibition of cyclic GMP-dependent 
vaso-relaxation by the TP receptor agonist is probably mediated through 
activation ofROK and phosphodiesterases. 
3. The presence of periadventitial adipose can partially reduce the TP 
receptor-activated inhibition of cyclic GMP-dependent vaso-relaxation in 
endothelium-removed rat aortic rings. 
4. The presence of periadventitial fat modulates cyclic GMP-dependent 
vaso-relaxation by directly or indirectly opening K+ channels and such 
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